Targeted next‐generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas

• DOI: 10.1002/path.4344
• Publication Date: 2014-03-06T15:22:43Z
• Authors: Eliana Amato; Marco dal Molin; Andrea Mafficini; Jun Yu; Giuseppe Malleo; Borislav Rusev; Matteo Fassan; Davide Antonello; Yoshihiko Sadakari; Paola Castelli; Giuseppe Zamboni; Anirban Maitra; Roberto Salvia; Ralph H Hruban; Claudio Bassi; Paola Capelli; Rita T Lawlor; Michael Goggins; Aldo Scarpa
• Keywords: Adult; Male; DNA Mutational Analysis; 03 medical and health sciences; 0302 clinical medicine; IPMN,pancreatic tumours,NGS,biomarkers; Biomarkers, Tumor; Humans; Genetic Predisposition to Disease; Aged; Aged, 80 and over; High-Throughput Nucleotide Sequencing; Middle Aged; Original Papers; Immunohistochemistry; Carcinoma, Papillary; 3. Good health; Pancreatic Neoplasms; Phenotype; Mutation; Female; Neoplasm Grading; Neoplasms, Cystic, Mucinous, and Serous; Multiplex Polymerase Chain Reaction; Carcinoma, Pancreatic Ductal

AbstractIntraductal neoplasms are important precursors to invasive pancreatic cancer and provide an opportunity to detect and treat pancreatic neoplasia before an invasive carcinoma develops. The diagnostic evaluation of these lesions is challenging, as diagnostic imaging and cytological sampling do not provide accurate information on lesion classification, the grade of dysplasia or the presence of invasion. Moreover, the molecular driver gene mutations of these precursor lesions have yet to be fully characterized. Fifty‐two intraductal papillary neoplasms, including 48 intraductal papillary mucinous neoplasms (IPMNs) and four intraductal tubulopapillary neoplasms (ITPNs), were subjected to the mutation assessment in 51 cancer‐associated genes, using ion torrent semiconductor‐based next‐generation sequencing. P16 and Smad4 immunohistochemistry was performed on 34 IPMNs and 17 IPMN‐associated carcinomas. At least one somatic mutation was observed in 46/48 (96%) IPMNs; 29 (60%) had multiple gene alterations. GNAS and/or KRAS mutations were found in 44/48 (92%) of IPMNs. GNAS was mutated in 38/48 (79%) IPMNs, KRAS in 24/48 (50%) and these mutations coexisted in 18/48 (37.5%) of IPMNs. RNF43 was the third most commonly mutated gene and was always associated with GNAS and/or KRAS mutations, as were virtually all the low‐frequency mutations found in other genes. Mutations in TP53 and BRAF genes (10% and 6%) were only observed in high‐grade IPMNs. P16 was lost in 7/34 IPMNs and 9/17 IPMN‐associated carcinomas; Smad4 was lost in 1/34 IPMNs and 5/17 IPMN‐associated carcinomas. In contrast to IPMNs, only one of four ITPNs had detectable driver gene (GNAS and NRAS) mutations. Deep sequencing DNA from seven cyst fluid aspirates identified 10 of the 13 mutations detected in their associated IPMN. Using next‐generation sequencing to detect cyst fluid mutations has the potential to improve the diagnostic and prognostic stratification of pancreatic cystic neoplasms. © 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.